Use of NG2 (7.1) in AML as a tumor marker and its association with a poor prognosis

Cancer Genomics and Proteomics

Volumn 7, Issue 4, 2010, Pages 173-180

  Petrovici, Karin ^a   Graf, Michaela ^a   Hecht, Karin ^a   Reif, Susanne ^a   Pfister, Karin ^b   Schmetzer, Helga ^a,c  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF REGENSBURG   (Germany)

^c INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

11q23 aberration; Acute myeloid leukemia; NG2

Indexed keywords

MONOCLONAL ANTIBODY; NG2 ANTIBODY; TUMOR MARKER; UNCLASSIFIED DRUG; ANTIGEN; CHONDROITIN SULFATE PROTEOGLYCAN 4; PROTEOGLYCAN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALLOIMMUNITY; ARTICLE; BONE MARROW CELL; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CELL COUNT; CHROMOSOME ABERRATION; CONTROLLED STUDY; DISEASE COURSE; DISEASE FREE SURVIVAL; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; GENE EXPRESSION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; KARYOTYPE; MAJOR CLINICAL STUDY; MALE; MONONUCLEAR CELL; PROGNOSIS; ADOLESCENT; BONE MARROW; CHEMISTRY; CHROMOSOME 11; GENETICS; LEUKEMIA, MYELOID, ACUTE; METABOLISM; MIDDLE AGED; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS; BONE MARROW; CHROMOSOMES, HUMAN, PAIR 11; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; PROGNOSIS; PROTEOGLYCANS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 77955972713     PISSN: 11096535     EISSN: 17906245     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Grimwade D, Walker H and Oliver F: The importance of diagnostic cytogenetics on outcome in AML: analyses of 1612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 92: 2322-2333, 1998.
2. Wuchter C, Harbott J, Schoch C, Schnittger S, Borkhardt A, Karawajew L, Ratei R, Ruppert V, Haferlach T, Creutzig U, Dörken B and Ludwig WD: Detection of acute leukemia cells with mixed lineage leukemia (MLL) gene rearrangements by flow cytometry using monoclonal antibody NG2. Leukemia 14: 1232-1238, 2000.
3. Smith FO, Rauch C, Williams D, March CJ, Arthur D, Hilden J, Lampkin BC, Buckley CV, Woods WG, Dinndorf PA, Sorensen P, Kersey J, Hammond D and Bernstein ID: The human homologue of rat NG2, a chondroitin sulfate proteoglycan, is not expressed on the cell surface of normal hematopoietic cells but is expressed by acute myeloid leukemia blasts from poor-prognosis patients with abnormalities of chromosome band 11q23. Blood 87: 1123-1133, 1996.
4. Bennett JM, Catovsky D and Daniel MT: Proposed revised criteria for the classification of acute myeloid leukemia. Ann. Intern Med 103: 626-629, 1985.
5. Rothe G and Schmitz G (Working group on Flow cytometry and Image Analyses): Consensus protocol for the flow cytometric immunophenotyping of hematopoietic malignancies. Leukemia 10: 877-895, 1996.
6. Byrd JC, Mrozek K, Dodge RK, Carroll AJ, Edwards CG, Arthur DC, Pettanati MJ, Patil SR, Rao K, Watson MS, Koduru PRK, Moore JO, Stone RM, Mayer JR, Feldman EJ, Davey FR, Schiffer CA, Larson RA and Bloomfield CD: Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: Results from Cancer and Leukemia Group B 2002 (CALGB 8461). Blood 100: 4325-4336, 2002.
7. + cells in AML and B-lineage ALL and in their normal bone marrow counterparts. Eur J Haematol 66: 178-187, 2001.
8. Graf M, Reif S, K. Hecht K, Pelka-Fleischer R, Pfister K, Nuessler V and Schmetzer H: Low CD62L expression in acute myeloid leukemia (AML) correlates with a bad cytogenetic risk. Eur J Haematol 71: 366-376, 2003.
9. + hemopoietic cells. Leukemia Lymphoma 24: 11-25, 1996.
10. Hantschel M, Pfister K, Jordan A , Scholz R, Andreesen R, Schmitz G, Schmetzer H, Hiddemann W and Multhoff G: Hsp70 plasma membrane expression on primary tumor biopsy material and bone marrow of leukemic patients. Cell Stress Chaperones 5: 438-442, 2000.
11. Gonzales Garcia JR and Meza-Espinoza JP: Use of the International System for Human Cytogenetic Nomenclature (ISCN). Blood 108(12): 3952-3953, 2006.
12. Schoch C, Schnittger S, Klaus M, Kern W, Hiddemann W and Haferlach T: AML with 11q23/MLL abnormalities as defined by the WHO classification: incidence, partner chromosomes, FAB subtype, age distribution, and prognostic impact in an unselected series of 1897 cytogenetically analyzed AML cases. Blood 102(7): 2395-2402, 2003.
13. Mrozek K, Heinonen K, de la Chapelle A and Boomfield CD: Clinical significance of cytogenetics in acute myeloid leukemia. Semin Oncol 24: 17-31, 1997.
14. Mazumdar M and Glassman JR: Tutorial in biostatistics. Categorizing a prognostic variable: Review of methods, code for easy implementation and applications to decision-making about cancer treatment. Stat Med 19: 113-132, 2000.
15. Mauvieux L, Delabasse E, Bourquelot P, Radford-Weiss I, Bennaceur A, Flandrin G, Valensi F and MacIntyre EA: NG2 expression in MLL rearranged acute myeloid leukaemia is restricted to monoblastic cases. Brit. J Haematol 107: 674-676, 1999.
16. Hilden J, Smith F, Frestedt J, McGlennen R, Howells W, Sorensen P, Arthur D, Woods W, Buckley J, Bernstein I and Kersey J: MLL gene rearrangement, catogenetic 11q23 abnormalities, and expression of the NG2 molecule in infant acute myeloid leukemia. Blood 89(10): 3801-3805, 1997.
17. Neudenberger J, Hotfilder M, Rosemann A, Langebrake C, Reinhardt D, Pieters R, Schrauder A, Schrappe M, Röttgers S, Hasbott J and Vormoor J: Lack of epxression of the chondroitin sulphate proteoglycan neuron-glial antigen 2 on candidate stem cell populations in paediatric acute myeloid leukaemia/abn (11q23) and acute lympho-blastic leukaemia/t (4;11). Br J Haematol 133(3): 337-344, 2006.
18. Hrusak O and Porwit-MacDonald A: Antigen expression patterns reflecting genotype of acute leukemias. Leukemia 16: 1233-1258, 2002.
19. Behm F, Smith F, Raimondi S, Pui C and Bernstein I: Human homologue of the rat chondroitin sulfate proteoglycan, NG2, detected by monoclonal antibody NG2, identifies childhood acute lymphoblastic leukemias with t(4;11)(q21;q23) or t (11;19)(q23;p13) and MLL gene rearrangements. Blood 87(3): 1134-1139, 1996.